CERO THERAPEUTICS HOLDINGS, INC. (CERO): Nasdaq/NYSE listing notice — Nasdaq Panel denies CERo Therapeutics continued listing; stock to suspend Oct 31

CERO THERAPEUTICS HOLDINGS, INC.

Shares of CERO common stock will be suspended from Nasdaq at open of trading on October 31, 2025.
Company has appealed to Nasdaq Listing and Hearing Review Council; also seeks OTC Markets trading.
$4.75M Series E Preferred financing contingent on Nasdaq listing; funding now uncertain.
Early clinical data for CER-1236 in three AML patients shows rapid cell expansion and no toxicity.
Company reviewing cash resources and financing alternatives; no assurance of funding.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

October 29, 2025, the Company received the determination of the Hearings Panel to deny the Company’s request for the continued listing of its common stock. As a result, the common stock will be suspended from trading on Nasdaq at open of trading on October 31, 2025. The Company has submitted a request for review of the Hearings Panel’s decision by the Nasdaq Listing and Hearing Review Council (the “ Council ”). The Company has also commenced the process of seeking to trade its shares of common stock on the OTC Markets. However, the Company can provide no assurance that the review by the Counci

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-103661

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.